



For release at 9:00 AM ET, November 8, 2010

Contact: Judy Mathew, +1 (678) 892-8807

RFS Pharma Awarded NIH Supplement Grant to Continue the Development of Novel Anti-HIV Drugs

Atlanta, GA, November 8, 2010 -- RFS Pharma, LLC, a clinical stage biopharmaceutical company, today announced the receipt of an extension R01 supplement grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The original R01 grant was awarded in 2007 for \$400,000 in association with two collaborative academic institutions to develop novel nucleoside reverse transcriptase inhibitors (NRTI) with excellent efficacy and safety profiles against drug resistant HIV-1. Based on the successful development and identification of numerous potential anti-HIV nucleoside analogs by in-depth studies evaluating structure-activity relationships, cellular toxicity and resistance selection, NIH has awarded an additional \$500,000 to the group for continued work in this area, of which approximately \$150,000 was dispersed to RFS Pharma.

“We are truly honored, in this highly competitive environment, to be a joint recipient of this prestigious extension grant, which is indicative of our progress to date”, said Dr. Steve Coats, Senior Director of Chemistry at RFS Pharma. “This collaborative effort has led to the discovery of several novel anti-HIV drugs and demonstrates the value of a focused close cooperation”, he added.

Nucleoside analogs have long been the cornerstone of antiviral therapy including HIV combination therapy and interfere with the incorporation of building blocks necessary for virus replication. Limitations of the eight FDA approved NRTIs for the treatment of HIV infection include the emergence of resistant mutants that render the current drugs ineffective, which drives the considerable interest in the development of new and novel nucleoside analogs with high potency, low toxicity, and high genetic barrier to resistance.

About RFS Pharma, LLC

RFS Pharma, LLC was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia. RFS Pharma is a privately owned biotech company committed to the discovery and development of antiviral agents and other human therapeutics. The company capitalizes on its

expertise in nucleoside chemistry to develop drugs to combat infections caused by drug-resistant HIV and hepatitis viruses. RFS Pharma's lead product candidate is amdoxovir, which is in advanced Phase 2 clinical studies for the treatment of HIV-1 infections. For further information about RFS Pharma, please refer to our website, www.rfspharma.com.

Forward-looking Statements

"Safe Harbor" Statement: Any statements in this press release that relate to the Companies' expectations are forward-looking statements, within the meaning of the US Private Securities Litigation Reform Act of 1995. Since this information may involve risks and uncertainties and be subject to change at any time, the Companies' actual results may differ materially from expected results. The Companies disclaim any obligation to update the statements contained in this press release.

SOURCE: RFS Pharma, LLC

###